Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10370 combinations in advanced solid tumors
NCT06963502Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hs-10370 in solid tumor, colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Number of Participants with Adverse Event(s) at 2 years. Planned start May 2025; status: not yet recruiting.
02
Drugs
hs-10370
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06963502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963502.